Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.
Using Genotype-Tissue Expression project samples, researchers put together gene regulatory networks for 29 tissue types, uncovering extensive sex-related regulatory differences.
Molecular Assemblies will combine its chemistries with Codexis' enzyme improvement platform in order to create a process for the enzymatic synthesis of DNA.
The latest group includes several firm developing genomics tools or diagnostics, but COVID-19 is preventing them from accessing their lab space for the time being.
The assay will identify patients with mutations in HER2 who may be eligible for treatment with a HER2-directed antibody-drug-conjugate developed by Daiichi.
Along with significantly mutated genes across cutaneous melanoma cases, researchers saw loss-of-function mutations in the X chromosome gene DDX3X in tumors from male patients.
RNA-seq of ascites from ovarian cancer patients uncovered shared inflammatory programs and suggested a JAK/STAT pathway inhibitor has antitumor activity.
Last week, GenomeWeb's readers were most interested in a judge granting Illumina a preliminary injunction to prevent BGI from distributing its sequencing platforms in the US.
The companies are developing a lung cancer liquid biopsy assay that will run on desktop sequencers, with plans to apply for regulatory clearance in China.
The tests are designed to detect regions in the SARS-CoV-2 genome in respiratory samples or antibodies against the virus in human serum, plasma, or blood.
Researchers identified secondary or incidental findings in just over 3 percent of the nearly 22,000 EMERGE III participants, who were profiled with a 109-gene panel.
Because of coronavirus-related shutdowns of customer labs, the San Diego-based firm saw decreased revenues in all geographic regions, especially outside the US.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
